Clinical Trials: Gynecological Cancers
Recurrent Disease - Cervical Cancer
Principal Investigator:
Dr. Carolyn Runowicz
Title:
A Phase II Study of Oxaliplatin in Combination with
Paclitaxel in patients with Locally Recurrent or Metastatic
Cervical Cancer
Description:.
This Phase II study is testing a new chemotherapy regimen
with Oxaliplatin and Paclitaxel for patients with locally
recurrent or metastatic cancer of the cervix. This study is
sponsored by the National Cancer Institute.
Length/Duration: Until disease progression
Compensation:
None
Location:
Neag
Comprehensive Cancer Center at the University of Connecticut
Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB#: 04-066
Sponsor:
National
Cancer Institute (NCI)
Screening - Ovarian Cancer
Principal Investigator:
Dr. Carolyn Runowicz
Title:
Collection of Clinical Samples from Patients at High Risk
for Ovarian Cancer for Biomarker Studies
Description:
The purpose of this study to determine the clinical utility
of a panel of ovarian cancer markers to screen patients at
high-risk for the development of ovarian cancer. This study
will examine blood taken from patients with and without
ovarian cancer and analyzed for the presence or absence of
the identified markers.
Length/Duration:
1 hour
Compensation:
None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB #: 06-160
Sponsor:
Tripath
Consolidation therapy - Ovarian
Cancer
Principal Investigator:
Dr. Zihai Li
Title: A
Phase I study of tumor-derived Heat Shock Protein gp96,
alone or in conjunction with GM-CSF, for the treatment of
patients with Stage III and IV ovarian cancer after
effective chemotherapy.
Description:
This is for women that have successfully been treated with
chemotherapeutics for ovarian cancer. The study aims to
determine if treating these women with a vaccine will help
to prevent the disease from recurring.
Length/Duration:
8 weeks of therapy followed by up to 2 years
of follow-up
Compensation:
None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB #: 03-077
Sponsor:
Investigator-initiated
Consolidation therapy - Ovarian
Cancer
Principal Investigator:
Dr. Carolyn Runowicz
Title: A
Phase II Study of OSI 774 in Combination with Carboplatin
and Paclitaxel in Patients with Ovarian, Cancer of the
Fallopian Tube or Primary Peritoneal Carcinoma
Description:
A phase II study of OSI 774 in combination with carboplatin
and paclitaxel in patients with ovarian, cancer of the
fallopian tube or primary peritoneal carcinoma
Length/Duration:
Up to 1½ years of treatment
Compensation:
None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB #: 04-082
Sponsor:
National Cancer Institute (NCI)
Second-line Therapy - Ovarian Cancer
Principal Investigator:
Dr. Carolyn Runowicz
Title: Randomized study of TLK286 (Telcyta) in combination with Carboplatin (paraplatin) versus Liposomal Doxorubicin (Doxil) as second-line therapy in platinum
refractory or resistant ovarian cancer
Description: This study will compare the effectiveness of an experimental compound (TLK286)
in combination with Carbo/Taxel against liposomal doxorubicin (Doxil) for women with platinum refractory
ovarian cancer. Women will be randomly placed into either group for their treatment.
Length/Duration:
Patients will receive treatment every 4 weeks until either their disease progresses or they can no longer tolerate the treatment.
Compensation:
None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB #: 05-212
Sponsor: Telik, Inc.
|
Research
done today will be the standard treatments of tomorrow.